Search
Now showing items 1-1 of 1
Modelling population-level impact to inform target product profiles for childhood malaria vaccines.
(2018-07-13)
BACKGROUND: The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5-17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot ...